This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Psychiatry  • Injury Prevention & Control  • Tobacco  • Quality of Care  • Patient Safety/ Medical Error  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Bridget M. Kuehn

JAMA. 2009;302(8):834.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

As reports of suicide and other serious psychiatric adverse events among patients taking the smoking cessation drug varenicline continue to mount, the US Food and Drug Administration (FDA) is requiring a boxed warning on the drug's label to alert physicians and patients to these risks.

The FDA's decision to require its strongest type of warning on labeling for varenicline comes after several efforts by the agency since 2007 to alert physicians and patients to psychiatric risks associated with the widely prescribed drug. The new labeling will prominently warn of the risk of behavioral changes, depression, hostility, aggression, suicidal thoughts, and suicide in patients taking the drug. A similar warning is also being added to the label of bupropion, an antidepressant and smoking cessation therapy that already carried a warning about suicidality in patients treated with the drug for depression.

The revised labeling for varenicline also will include . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sibutramine for weight gain attenuation during smoking cessation with varenicline: A pilot study
Sood et al.
Nicotine Tob Res 2009;0:ntp162v2-ntp162.
ABSTRACT | FULL TEXT